Welcome to our dedicated page for Mediwound news (Ticker: MDWD), a resource for investors and traders seeking the latest updates and insights on Mediwound stock.
MediWound Ltd. develops and commercializes enzymatic, non-surgical therapies for tissue repair as a global biotechnology company. Its FDA-approved biologic NexoBrid is indicated for enzymatic removal of eschar in thermal burns and is marketed in the United States, European Union, Japan, and other international markets.
News about MDWD commonly covers financial results, corporate updates, NexoBrid commercialization and distribution, BARDA-supported burn-care activity, and the development of EscharEx, an investigational bromelain-based therapy for debridement of chronic and hard-to-heal wounds. Company updates also include clinical data presentations, wound-care conference activity, regulatory filings, and shareholder communications.
MediWound Ltd. (Nasdaq: MDWD) reported Q3 2021 revenues of $6.4 million, a 4% decline from Q3 2020. Year-to-date revenues rose by 21% to $18.3 million. The company maintains $13.9 million in cash and short-term investments as of September 30, 2021. A regulatory path for the resubmission of NexoBrid's Biologics License Application (BLA) is established, targeted for mid-2022. The EscharEx Phase 2 program's top-line results are now expected in Q1 2022. Notably, net loss for Q3 2021 was $3.3 million, or $0.12 per share.
MediWound Ltd. (Nasdaq: MDWD) will release its financial results for Q3 2021 on November 16, 2021, at 7:00 am ET. A conference call will follow at 8:30 am ET to discuss these results and address questions. MediWound focuses on biotherapeutic solutions for tissue repair, with products like NexoBrid® for burn treatment and EscharEx for chronic wounds in advanced development stages. The company aims to improve patient care through innovative therapies.
MediWound Ltd. (Nasdaq: MDWD) announced positive results from a peer-reviewed study published in the Journal of Wound Care, demonstrating that EscharEx is superior in removing chronic wound eschar compared to a commercial collagenase agent. Conducted using a novel porcine model, the study found that EscharEx achieved over 95% eschar removal within ten applications, while collagenase did not. This efficacy supports the ongoing U.S. Phase 2 study for treating venous leg ulcers, which is expected to report results in the first half of next year.
MediWound Ltd. (Nasdaq: MDWD), a biopharmaceutical company specializing in advanced therapeutic solutions for tissue repair, announced presentations at key investor conferences in September 2021. The company will participate in the 2021 Wells Fargo Virtual Healthcare Conference on September 9 at 8:00 a.m. ET and the H.C. Wainwright 23rd Annual Global Investment Conference with an on-demand presentation available starting September 13. The company focuses on innovative products like NexoBrid and EscharEx for burn care and wound management.
MediWound Ltd. (MDWD) reported second-quarter revenues of $6.1 million, marking a significant 50% increase year-over-year. The company maintained $17.2 million in cash and short-term investments. A positive interim assessment for the EscharEx Phase II clinical study was announced, with full enrollment expected by year-end 2021. Despite receiving a Complete Response Letter from the FDA for the NexoBrid BLA, positive results from the pediatric study reinforce its safety and efficacy. The first half of 2021 showed a 41% revenue increase to $11.9 million.
MediWound Ltd. (MDWD) will release its financial results for Q2 2021 on Aug. 10, 2021, at 7:00 am ET. A conference call is scheduled for the same day at 8:30 am ET to discuss these results and provide a corporate update. MediWound specializes in bio-therapeutic solutions for tissue repair and regeneration, notably NexoBrid® for burn treatment, which is marketed in the EU and pending in the U.S. Additionally, EscharEx for chronic wound care is in advanced development with promising trial results.
MediWound Ltd. (MDWD) announced a positive interim recommendation from the Independent Data Monitoring Committee (IDMC) regarding its EscharEx® U.S. phase 2 study for treating venous leg ulcers. The IDMC confirmed that the original enrollment target of 120 patients remains sufficient for statistical power, with no safety concerns reported. Full enrollment is expected by the end of 2021, and data readout is anticipated in the first half of 2022. EscharEx is designed to be a non-surgical therapy for chronic wound management, with potential to replace current standard care.
MediWound Ltd. (Nasdaq: MDWD) has initiated a phase I/II clinical study of MW005 to treat low-risk Basal Cell Carcinoma (BCC). This open-label, randomized trial aims to assess safety, tolerability, and preliminary efficacy. Up to 32 patients will participate at three U.S. clinical centers. Concurrently, a phase II trial at Soroka Medical Center will study MW005 in non-melanoma skin cancers. Results from both studies are expected by the end of 2021. BCC is the most common skin cancer in the U.S., with approximately 4.3 million cases annually.
MediWound Ltd. (Nasdaq: MDWD) announced positive topline results from its pivotal phase 3 pediatric study on NexoBrid for treating severe thermal burns in children. The study met all three primary endpoints with high statistical significance, demonstrating a substantially shorter time to complete eschar removal (0.99 days vs. 5.99 days for SOC) and significantly lower wound area needing surgical excision (1.5% vs. 48.1%). NexoBrid was well-tolerated, showing no adverse effects on wound healing. These findings reinforce NexoBrid's potential as a non-surgical treatment option for pediatric patients.
MediWound Ltd. (Nasdaq: MDWD) announced the publication of a peer-reviewed study on its wound debriding product, EscharEx, in the Wound Repair and Regeneration Journal. The phase 2 trial evaluated 73 patients with chronic wounds, demonstrating that EscharEx achieved a significantly higher incidence of complete debridement compared to a hydrogel vehicle, thereby meeting the study's primary endpoint. An interim assessment of the ongoing U.S. phase 2 adaptive design study for venous leg ulcers is expected by the end of July 2021. CEO Sharon Malka stated EscharEx shows potential to enhance chronic wound management.